Uncategorized
Novartis Pledges $480M To Expand China Presence, Following Eli Lilly and AstraZeneca
Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.
Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.